Today we're joined by Dr. Daniel Meyers of the University of Calgary who's here to discuss his new paper out now in the Journal of Cancer Policy. It's titled "Industry payments to US physicians for cancer therapeutics: An analysis of the 2016–2018 open payments datasets".

Industry payments: doi.org/10.1016/j.jcpo.2021.100283

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

3.73 CheckMate 577: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com